Antibody therapy phase I trial safety remains topical

By  

Inpharma, Vol. 1, Iss. 1555, 2006-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex: A Double-Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of Topically Applied Rapamycin

By >   Hebert Adelaide A.   Roberson Joan  

Drugs in R&D, Vol. 12, Iss. 3, 2012-09 ,pp. : 121-126

Adis International

Access to resources Recommend Favorite

Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis: An Open-Label Extension of a Phase IIIb Trial

By Hamilton Tiffani  

Drug Safety, Vol. 31, Iss. 8, 2008-01 ,pp. : 715-726

Adis International

Access to resources Recommend Favorite

Phase III Trial of Eprotirome: Discontinued for Safety Concerns

By Sweetlove Mel  

Pharmaceutical Medicine, Vol. 26, Iss. 3, 2012-06 ,pp. : 185-187

Adis International

Access to resources Recommend Favorite

Cytotoxic Etherphospholipid Analogues - A phase I trial

By Berkovic D.  

General Pharmacology, Vol. 31, Iss. 4, 1998-10 ,pp. : 511-517

Elsevier

Access to resources Recommend Favorite